Reversing Hypertriglyceridemia and Hepatic Steatosis in Dysmetabolic NHPs with a Controlled-Release Mitochondrial Protonophore (CRMP)

Reversing Hypertriglyceridemia and Hepatic Steatosis in Dysmetabolic NHPs with a Controlled-Release Mitochondrial Protonophore (CRMP)

ON DEMAND

Leigh Goedeke, PhD reviews translational nonhuman primate models of nonalcoholic fatty liver disease (NAFLD) and metabolic syndrome, sharing data demonstrating the therapeutic effects of a Controlled-Release Mitochondrial Protonophore (CRMP).

Nonalcoholic fatty liver disease (NAFLD), a condition in which fatty acids accumulate in the liver, can lead to potentially serious conditions including nonalcoholic steatohepatitis (NASH) and type-2 diabetes (T2D). While caloric restriction has been shown to be effective in humans, the strict dietary requirements can be very difficult to maintain in the long-term. Novel therapies are therefore required to reverse NAFLD, insulin resistance and diabetes.

In this webinar hosted by CrownBio, Dr. Leigh Goedeke of Yale University discusses the development of controlled-release mitochondrial protonophore (CRMP) treatments for NAFLD and type-2 diabetes in diet-induced NHP models of obesity. In addition, she presents data supporting the safety and therapeutic effects of CRMP, including the reversal of hypertriglyceridemia, fatty liver, and hepatic inflammation.

Key Learning Objectives:

  • The translational relevance of NHP models of NAFLD and metabolic syndrome
  • How Controlled-Release Mitochondrial Protonophores (CRMPs) reduce dyslipidemia and glucose production
  • Study data demonstrating the therapeutic effects of CRMP treatment for NAFLD and type 2 diabetes
  • How Positional Isotopomer NMR Tracer Analysis (PINTA) is used to assess hepatic mitochondrial metabolism

This webinar is most relevant to:

  • Preclinical scientists interested in learning more about CRMP and PINTA
  • Pharmacological researchers interested in therapies for NAFLD/NASH or type 2 diabetes
  • Scientists using NHPs or large animal models to study NAFLD/NASH

Leigh Goedeke, PhD

Postdoctorl Fellow,
Yale School of Medicine

Dr. Leigh Goedeke is a Postdoctoral Fellow at Yale School of Medicine, in the laboratory of Dr. Gerald Shulman. With extensive experience in multiple metabolic disease indications, Dr. Goedeke specializes in the interplay between hepatic steatosis, insulin resistance, type 2 diabetes, and cardiovascular disease. As part of the Shulman lab, Dr. Goedeke uses stable isotope tracer methods to understand how alterations in metabolic fluxes contribute to the pathogenesis of insulin resistance and is investigating the therapeutic potential of liver-targeted mitochondrial uncoupling agents to reverse metabolic syndrome.

Dr. Goedeke received her Ph.D. in Biomedical Sciences from New York University School of Medicine where she identified and characterized novel genes and miRNAs involved in lipid metabolism using functional genomic screens. She has authored over 30 publications, and holds a patent in a specialized oligonucleotide as a therapeutic tool for treating dyslipidemias and cardiovascular diseases